ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1459

Multiple Cytokine Profiling Predicts The Effectiveness Of Switching Biologics In Rheumatoid Arthritis

Kensuke Koyama1, Katsunori Ikari1, Atsuo Taniguchi2, Shigeki Momohara2 and Hisashi Yamanaka1, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Biologic agents, cytokines and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy II

Session Type: Abstract Submissions (ACR)

Background/Purpose: There is some rheumatoid arthritis (RA) patients with poor responses to certain biologics which requires switching to another biologics. However, there is no solid evidence to support such switching of biologics. We examined cytokine profiles for these patients to identify effective switching of biologics.
Methods: IORRA cohort is a hospital-based large observational cohort of Japanese RA patients.Clinical information and laboratory data are collected biannually. The patients who had switched biologics were chosen from the cohort. Serum levels of various cytokines (TNF alpha, IL-6, IL-17A, IL-1 beta, IL-8, MCP-1, TNF R1, TNF R2) before switching biologics were measured by using multiplex cytokine array system. Multiple regression model were used to examine following variables (objective variable: delta DAS28, explaining variable: previous DAS28, various cytokines) in several switching patterns. Statistical significant was established at p< 0.05.
Results: Eighty seven patients were identified as first TNF alpha antibody failure (infliximab: 50, etanercept: 21, adalimumab: 16).  Thirty patients switched from one anti-TNF alpha antibody to another anti-TNF alpha agent, 36 switched to an anti-IL-6 antibody. Delta DAS28 (Post DAS28-Pre DAS28) set up in accordance with regression coefficient is shown Figure 1. Constant term, IL-17A and IL-1 beta was identified as significant regression coefficients in switching from one anti-TNF antibody to another anti-TNF alpha agent group. Pre DAS28 was only extracted as significant regression coefficients in switching from one anti-TNF antibody to an anti-IL-6 antibody group. Pre DAS28, TNF alpha, IL-8, MCP-1, TNFR1 and TNFR2 were chosen in concordance with EULAR good and moderate response cases in this group. It was impossible to examine the patients switching from etanercept because of the small number.
Conclusion: Our results suggest that cytokine profile maybe an effective way of predicting of possible switching from one biologic to another. Inefficient biologics switching may expose patients to further unnecessary joint destruction and cost.


Disclosure:

K. Koyama,
None;

K. Ikari,
None;

A. Taniguchi,
None;

S. Momohara,
None;

H. Yamanaka,

Daiichi Sankyo, Mitsubishi Tanabe Pharma, Abbott Japan, Eisai, Takeda Pharmaceutical, Janssen Pharmaceutical, Hoffmann-La Roche, and Pfizer,

8,

Abbott Japan, Asahikasei Kuraray Medical, Asahikasei Pharma, Astellas Pharma, AstraZeneca, MSD, Chugai Pharmaceutical, Daiichi Fine Chemical, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, GlaxoSmithKline, Janssen Pharmaceutical, Japan Tobacco, Kaken P,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/multiple-cytokine-profiling-predicts-the-effectiveness-of-switching-biologics-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology